Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 530

1.

Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer.

Haentschel M, Boeckeler M, Ehab A, Wagner R, Spengler W, Steger V, Boesmueller H, Horger M, Lewis RA, Fend F, Kanz L, Bonzheim I, Hetzel J.

Lung Cancer. 2020 Mar;141:56-63. doi: 10.1016/j.lungcan.2019.12.008. Epub 2020 Jan 7.

2.

Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party.

Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, Daikeler T, Schmalzing M, Schroers R, Martin T, Pugnet G, Simoes B, Michonneau D, Marijt EWA, Lioure B, Bay JO, Snowden JA, Rovira M, Huynh A, Onida F, Kanz L, Marjanovic Z, Farge D.

Haematologica. 2020 Jan 16. pii: haematol.2019.230128. doi: 10.3324/haematol.2019.230128. [Epub ahead of print]

3.

Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.

Roerden M, Sökler M, Kanz L, Bethge W, Vogel W, Walz JS.

Ann Hematol. 2020 Feb;99(2):265-276. doi: 10.1007/s00277-019-03900-x. Epub 2020 Jan 2.

PMID:
31897675
4.

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.

Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH.

J Clin Oncol. 2020 Jan 20;38(3):248-256. doi: 10.1200/JCO.19.01294. Epub 2019 Dec 5.

PMID:
31804876
5.

Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis.

Pecher AC, Kettemann F, Asteriti E, Schmid H, Duerr-Stoerzer S, Keppeler H, Henes JC, Klein R, Hinterleitner C, Secker KA, Schneidawind C, Kanz L, Schneidawind D.

Arthritis Res Ther. 2019 Oct 15;21(1):212. doi: 10.1186/s13075-019-1991-y.

6.

Disease progression and defects in primary hemostasis as major cause of bleeding in multiple myeloma.

Hinterleitner C, Pecher AC, Kreißelmeier KP, Budde U, Kanz L, Kopp HG, Jaschonek K.

Eur J Haematol. 2020 Jan;104(1):26-35. doi: 10.1111/ejh.13331. Epub 2019 Dec 5.

PMID:
31541609
7.

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.

Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom.

Leukemia. 2019 Nov;33(11):2710-2719. doi: 10.1038/s41375-019-0537-2. Epub 2019 Aug 28.

PMID:
31462732
8.

The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience.

Roerden M, Walz JS, Müller MR, Sökler M, Federmann B, Kanz L, Bethge W, Vogel W.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2595-2604. doi: 10.1007/s00432-019-02999-9. Epub 2019 Aug 13.

PMID:
31410605
9.

The German National Registry of Primary Immunodeficiencies (2012-2017).

El-Helou SM, Biegner AK, Bode S, Ehl SR, Heeg M, Maccari ME, Ritterbusch H, Speckmann C, Rusch S, Scheible R, Warnatz K, Atschekzei F, Beider R, Ernst D, Gerschmann S, Jablonka A, Mielke G, Schmidt RE, Schürmann G, Sogkas G, Baumann UH, Klemann C, Viemann D, von Bernuth H, Krüger R, Hanitsch LG, Scheibenbogen CM, Wittke K, Albert MH, Eichinger A, Hauck F, Klein C, Rack-Hoch A, Sollinger FM, Avila A, Borte M, Borte S, Fasshauer M, Hauenherm A, Kellner N, Müller AH, Ülzen A, Bader P, Bakhtiar S, Lee JY, Heß U, Schubert R, Wölke S, Zielen S, Ghosh S, Laws HJ, Neubert J, Oommen PT, Hönig M, Schulz A, Steinmann S, Schwarz K, Dückers G, Lamers B, Langemeyer V, Niehues T, Shai S, Graf D, Müglich C, Schmalzing MT, Schwaneck EC, Tony HP, Dirks J, Haase G, Liese JG, Morbach H, Foell D, Hellige A, Wittkowski H, Masjosthusmann K, Mohr M, Geberzahn L, Hedrich CM, Müller C, Rösen-Wolff A, Roesler J, Zimmermann A, Behrends U, Rieber N, Schauer U, Handgretinger R, Holzer U, Henes J, Kanz L, Boesecke C, Rockstroh JK, Schwarze-Zander C, Wasmuth JC, Dilloo D, Hülsmann B, Schönberger S, Schreiber S, Zeuner R, Ankermann T, von Bismarck P, Huppertz HI, Kaiser-Labusch P, Greil J, Jakoby D, Kulozik AE, Metzler M, Naumann-Bartsch N, Sobik B, Graf N, Heine S, Kobbe R, Lehmberg K, Müller I, Herrmann F, Horneff G, Klein A, Peitz J, Schmidt N, Bielack S, Groß-Wieltsch U, Classen CF, Klasen J, Deutz P, Kamitz D, Lassay L, Tenbrock K, Wagner N, Bernbeck B, Brummel B, Lara-Villacanas E, Münstermann E, Schneider DT, Tietsch N, Westkemper M, Weiß M, Kramm C, Kühnle I, Kullmann S, Girschick H, Specker C, Vinnemeier-Laubenthal E, Haenicke H, Schulz C, Schweigerer L, Müller TG, Stiefel M, Belohradsky BH, Soetedjo V, Kindle G, Grimbacher B.

Front Immunol. 2019 Jul 19;10:1272. doi: 10.3389/fimmu.2019.01272. eCollection 2019.

10.

Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7770):E19. doi: 10.1038/s41586-019-1475-x.

PMID:
31367045
11.

Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner.

Jahnke S, Schmid H, Secker KA, Einhaus J, Duerr-Stoerzer S, Keppeler H, Schober-Melms I, Baur R, Schumm M, Handgretinger R, Bethge W, Kanz L, Schneidawind C, Schneidawind D.

Front Immunol. 2019 Jul 9;10:1542. doi: 10.3389/fimmu.2019.01542. eCollection 2019.

12.

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7768):254-259. doi: 10.1038/s41586-019-1410-1. Epub 2019 Jul 17. Erratum in: Nature. 2019 Aug 1;:.

13.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2167-2171. doi: 10.1016/j.bbmt.2019.06.034. Epub 2019 Jul 5.

PMID:
31284069
14.

Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Axt L, Naumann A, Toennies J, Haen SP, Vogel W, Schneidawind D, Wirths S, Moehle R, Faul C, Kanz L, Axt S, Bethge WA.

Bone Marrow Transplant. 2019 Nov;54(11):1805-1814. doi: 10.1038/s41409-019-0544-y. Epub 2019 May 14.

PMID:
31089279
15.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.

Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N; CMWP of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208. doi: 10.1016/j.bbmt.2019.03.024. Epub 2019 Mar 28.

PMID:
30930192
16.

G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients.

Schneidawind C, Jahnke S, Schober-Melms I, Schumm M, Handgretinger R, Faul C, Kanz L, Bethge W, Schneidawind D.

Br J Haematol. 2019 Jul;186(1):60-71. doi: 10.1111/bjh.15881. Epub 2019 Mar 27.

PMID:
30916396
17.

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.

Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N.

Haematologica. 2019 May;104(5):929-936. doi: 10.3324/haematol.2018.200808. Epub 2019 Jan 17.

18.

Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34+ cells preceding leukemic transformation.

Dannenmann B, Zahabi A, Mir P, Oswald B, Bernhard R, Klimiankou M, Morishima T, Schulze-Osthoff K, Zeidler C, Kanz L, Lachmann N, Moritz T, Welte K, Skokowa J.

Exp Hematol. 2019 Mar;71:51-60. doi: 10.1016/j.exphem.2018.12.006. Epub 2019 Jan 4.

PMID:
30615903
19.

Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia.

Müller DJ, Wirths S, Fuchs AR, Märklin M, Heitmann JS, Sturm M, Haap M, Kirschniak A, Sasaki Y, Kanz L, Kopp HG, Müller MR.

J Leukoc Biol. 2019 Mar;105(3):531-538. doi: 10.1002/JLB.2AB0218-076RR. Epub 2018 Dec 17.

PMID:
30556925
20.

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS.

Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10.

PMID:
30530751
21.

Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.

Schmid H, Schneidawind C, Jahnke S, Kettemann F, Secker KA, Duerr-Stoerzer S, Keppeler H, Kanz L, Savage PB, Schneidawind D.

Front Immunol. 2018 Aug 6;9:1817. doi: 10.3389/fimmu.2018.01817. eCollection 2018.

22.

First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications.

Löffler MW, Steinhilber J, Hilke FJ, Haen SP, Bösmüller H, Montes-Mojarro IA, Bonzheim I, Stäbler A, Faust U, Grasshoff U, Königsrainer I, Rammensee HG, Kanz L, Königsrainer A, Beckert S, Riess O, Schroeder C.

BMC Med Genet. 2018 Aug 15;19(1):144. doi: 10.1186/s12881-018-0651-4.

23.

Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.

Schneidawind C, Hagmaier V, Faul C, Kanz L, Bethge W, Schneidawind D.

Ann Hematol. 2018 Dec;97(12):2491-2500. doi: 10.1007/s00277-018-3454-y. Epub 2018 Jul 31.

PMID:
30066039
24.

Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient.

Hinterleitner C, Steurer M, Dörfel D, Heitmann J, Kreisselmeier KP, Müller K, Kopp HG, Wirths S, Haap M, de Fend LQ, Horger M, Rodriguez-Galindo C, Kanz L, Müller MR.

Ann Hematol. 2019 Jan;98(1):227-230. doi: 10.1007/s00277-018-3421-7. Epub 2018 Jul 6. No abstract available.

PMID:
29980874
25.

Impact of surgery in patients with metastatic soft tissue sarcoma: A monocentric retrospective analysis.

Wigge S, Heißner K, Steger V, Ladurner R, Traub F, Sipos B, Bösmüller H, Kanz L, Mayer F, Kopp HG.

J Surg Oncol. 2018 Jul;118(1):167-176. doi: 10.1002/jso.25115. Epub 2018 Jun 28.

26.

Paradigm Shift in the Management of Irresectable Colorectal Liver Metastases: Living Donor Auxiliary Partial Orthotopic Liver Transplantation in Combination With Two-stage Hepatectomy (LD-RAPID).

Königsrainer A, Templin S, Capobianco I, Königsrainer I, Bitzer M, Zender L, Sipos B, Kanz L, Wagner S, Nadalin S.

Ann Surg. 2019 Aug;270(2):327-332. doi: 10.1097/SLA.0000000000002861.

PMID:
29916882
27.

Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.

Löffler MW, Kowalewski DJ, Backert L, Bernhardt J, Adam P, Schuster H, Dengler F, Backes D, Kopp HG, Beckert S, Wagner S, Königsrainer I, Kohlbacher O, Kanz L, Königsrainer A, Rammensee HG, Stevanović S, Haen SP.

Cancer Res. 2018 Aug 15;78(16):4627-4641. doi: 10.1158/0008-5472.CAN-17-1745. Epub 2018 May 22.

28.

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S, Walz JS.

Oncoimmunology. 2018 Feb 14;7(4):e1316438. doi: 10.1080/2162402X.2017.1316438. eCollection 2018.

29.

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia.

Kampa-Schittenhelm KM, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm MM.

Oncotarget. 2018 Jan 31;9(14):11876-11882. doi: 10.18632/oncotarget.24376. eCollection 2018 Feb 20.

30.

[Follow-up Care in Cancer: Selected Solid Tumors and Hematological Neoplasias].

Rörden M, Hinterleitner C, Metzger J, Kanz L.

Dtsch Med Wochenschr. 2018 Mar;143(5):334-342. doi: 10.1055/s-0043-124254. Epub 2018 Mar 5. German.

PMID:
29506300
31.

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M.

Leukemia. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26.

32.

T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT).

Sestili S, Labopin M, Ruggeri A, Velardi A, Ciceri F, Maertens J, Kanz L, Aversa F, Lewalle P, Bunjes D, Mohty M, Nagler A.

Cancer. 2018 May 15;124(10):2142-2150. doi: 10.1002/cncr.31310. Epub 2018 Feb 22.

33.

Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.

Glaeser L, Henes J, Kötter I, Vogel W, Kanz L, Klein R.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):28-35. Epub 2018 Feb 13.

34.

Low plasma protein Z levels are associated with an increased risk for perioperative bleedings.

Hinterleitner C, Kreisselmeier KP, Pecher AC, Mauz PS, Kanz L, Kopp HG, Jaschonek KG.

Eur J Haematol. 2018 May;100(5):403-411. doi: 10.1111/ejh.13031. Epub 2018 Mar 26.

PMID:
29360177
35.

Haploidentical transplant in patients with myelodysplastic syndrome.

Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, Blaise D, Güllbas Z, Gonzáles Muñiz S, Michallet M, Velardi A, Koster L, Maertens J, Sierra J, Selleslag D, Radujkovic A, Díez-Martin JL, Kanz L, Arroyo CH, Niederwieser D, Huang H, McDonald A, de Witte T, Koc Y, Kröger N.

Blood Adv. 2017 Sep 27;1(22):1876-1883. doi: 10.1182/bloodadvances.2017007146. eCollection 2017 Oct 10.

36.

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.

Walz JS, Kowalewski DJ, Backert L, Nelde A, Kohlbacher O, Weide B, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Leuk Lymphoma. 2018 Aug;59(8):1949-1958. doi: 10.1080/10428194.2017.1403022. Epub 2018 Jan 3.

PMID:
29295645
37.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kröger N.

Haematologica. 2018 Feb;103(2):237-245. doi: 10.3324/haematol.2017.168716. Epub 2017 Nov 3.

38.

NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia.

Märklin M, Heitmann JS, Fuchs AR, Truckenmüller FM, Gutknecht M, Bugl S, Saur SJ, Lazarus J, Kohlhofer U, Quintanilla-Martinez L, Rammensee HG, Salih HR, Kopp HG, Haap M, Kirschniak A, Kanz L, Rao A, Wirths S, Müller MR.

Nat Commun. 2017 Oct 2;8(1):755. doi: 10.1038/s41467-017-00830-y.

39.

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.

Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Salwender H, Hebart H, Straka C, Knop S.

Br J Haematol. 2017 Nov;179(4):586-597. doi: 10.1111/bjh.14920. Epub 2017 Sep 29.

PMID:
28961309
40.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

41.

Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.

Schneidawind C, Duerr-Stoerzer S, Faul C, Kanz L, Weisel K, Bethge W, Schneidawind D.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12994. Epub 2017 May 26.

PMID:
28470884
42.

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.

Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, Cardona Gloria Y, Langerak AW, Muggen AF, Claus R, Bonzheim I, Fend F, Salih HR, Kanz L, Rammensee HG, Stevanović S, Weber AN.

Oncoimmunology. 2016 Dec 23;6(3):e1219825. doi: 10.1080/2162402X.2016.1219825. eCollection 2017.

43.

The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.

Both A, Krauter J, Damm F, Thol F, Göhring G, Heuser M, Ottmann O, Lübbert M, Wattad M, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Brugger W, Schlegelberger B, Heil G, Ganser A, Wagner K.

Ann Hematol. 2017 Jun;96(6):895-904. doi: 10.1007/s00277-017-2967-0. Epub 2017 Mar 22.

PMID:
28331964
44.

Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.

Haen SP, Groh C, Schumm M, Backert L, Löffler MW, Federmann B, Faul C, Dörfel D, Vogel W, Handgretinger R, Kanz L, Bethge WA.

Ann Hematol. 2017 May;96(5):817-827. doi: 10.1007/s00277-017-2941-x. Epub 2017 Feb 28.

PMID:
28247058
45.

Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.

Haen SP, Eyb V, Mirza N, Naumann A, Peter A, Löffler MW, Faul C, Vogel W, Bethge WA, Rammensee HG, Kanz L, Heni M.

J Cancer Res Clin Oncol. 2017 May;143(5):759-771. doi: 10.1007/s00432-017-2348-z. Epub 2017 Feb 16.

PMID:
28210842
46.

Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.

Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczulla AM, Reich S, Jacob F, Perner S, Moch H, Fehm TN, Kanz L, Schulze-Osthoff K, Lengerke C.

Cancer Res. 2017 Apr 15;77(8):2148-2160. doi: 10.1158/0008-5472.CAN-16-0593. Epub 2017 Feb 16.

47.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS.

Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918.

48.

Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine.

Pecher AC, Igney-Oertel A, Kanz L, Henes J.

Scand J Rheumatol. 2017 Sep;46(5):407-409. doi: 10.1080/03009742.2016.1245780. Epub 2017 Jan 18. No abstract available.

PMID:
28097903
49.

Thymic findings before and after autologous stem cell transplantation for severe systemic sclerosis: a retrospective study using computed tomography in the pre- and post-transplantation setting.

Henes JC, Wirths S, Vogel W, Xenitidis T, Kanz L, Horger M.

Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):11-12. Epub 2017 Jan 13. No abstract available.

50.

GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling.

Koch C, Samareh B, Morishima T, Mir P, Kanz L, Zeidler C, Skokowa J, Welte K.

Ann Hematol. 2017 Mar;96(3):345-353. doi: 10.1007/s00277-016-2894-5. Epub 2016 Dec 14.

PMID:
27966038

Supplemental Content

Support Center